FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385658110> ?p ?o ?g. }

• W4385658110 endingPage "e05170e0" @default.
• W4385658110 startingPage "e05170e0" @default.
• W4385658110 abstract "Background: EDIT-301, an investigational gene-edited autologous hematopoietic stem cell medicine, has a unique genomic modification at the γ-globin gene (HBG1/HBG2) promoters where multiple naturally occurring mutations for hereditary persistence of fetal hemoglobin (HPFH) reside to reactivate γ-globin expression and increase HbF production. EDIT-301 is manufactured using a highly efficient and specific, proprietary AsCas12a. In preclinical studies, editing of this region in CD34+ cells from patients with SCD led to ≥80% editing, robust HbF production, no off-target editing, and significantly reduced sickling of EDIT-301-derived erythroid progeny. Aims: The RUBY trial (NCT04853576), a Phase I/II, multicenter, open-label, single-arm study, evaluates the safety, tolerability, and efficacy of EDIT-301 in subjects with severe SCD. Four subjects have received EDIT-301 treatment. Preliminary clinical data on gene editing, safety, and efficacy are reported. Methods: Subjects 18–50 years old must have a diagnosis of severe SCD defined as ≥2 severe vaso-occlusive events (VOEs) per year in the 2-year period prior to informed consent. Autologous CD34+ hematopoietic stem and progenitor cells are collected by apheresis after plerixafor mobilization and edited at the HBG1/HBG2 promoter with AsCas12a. After myeloablative conditioning with busulfan, subjects received a single infusion of EDIT-301 (≥3 × 106 CD34+ cells/kg), and were monitored for engraftment, total hemoglobin (Hb), HbF production, mean HbF concentration/F-cell (MCH-F/F-cell), percentage of F-cells, markers of hemolysis, transfusion requirement, VOEs, and adverse events (AEs) for 24-months. Results: Editing of CD34+ cells using AsCas12a resulted in ≥80% editing in study participants’ cells (N=8). As of March 1, 2023, Subjects 1 and 2 are 8- and 4-months post-EDIT-301 infusion, respectively, and Subjects 3 and 4 are <1-month post-EDIT-301 infusion. Neutrophil and platelet engraftment were achieved within 23 and 19 days (Subject 1) and within 29 and 37 days (Subject 2) of EDIT-301 infusion, respectively. At last data points available, Subjects 1 and 2 had normal Hb concentrations, HbF levels >35% (Figure 1), MCH-F/F-cell >10.0 pg/F-cell, and no reported VOEs. Hb increased by 4.5 g/dL from baseline (BL) to 16.4 g/dL at 6 months (Subject 1) and increased by 3.6 g/dL from BL to 12.1 g/dL at 3 months post-EDIT-301 infusion (Subject 2). Percentage of F-cells was 96.5% at 6 months (Subject 1). All markers of hemolysis improved or normalized. Editing levels in peripheral blood nucleated cells were >80% in both subjects. The safety profile of EDIT-301 was consistent with myeloablative conditioning with busulfan, with no reported EDIT-301-related AEs and no serious adverse events (SAEs) after EDIT-301 infusion. Summary/Conclusion: These preliminary data demonstrate successful engraftment, a rapid and sustained increase in total Hb, HbF level, and percentage of F-cells, improvements in key markers of hemolysis, and a favorable safety profile in subjects treated with EDIT-301. These preliminary data demonstrated clinical proof of concept and are promising for the first clinical use of AsCas12a-based gene editing of the globin gene (HBG1/HBG2) promoters, thereby supporting further investigation of EDIT-301 in the RUBY clinical trial. Updated data will be presented.Keywords: Globin gene, Sickle cell disease, Gene therapy" @default.
• W4385658110 created "2023-08-09" @default.
• W4385658110 creator A5002240997 @default.
• W4385658110 creator A5014878595 @default.
• W4385658110 creator A5015387863 @default.
• W4385658110 creator A5020447229 @default.
• W4385658110 creator A5021909393 @default.
• W4385658110 creator A5040299600 @default.
• W4385658110 creator A5041000924 @default.
• W4385658110 creator A5049744314 @default.
• W4385658110 creator A5068601602 @default.
• W4385658110 creator A5073201681 @default.
• W4385658110 creator A5076450548 @default.
• W4385658110 creator A5088514992 @default.
• W4385658110 date "2023-08-01" @default.
• W4385658110 modified "2023-10-01" @default.
• W4385658110 title "S264: EDIT-301 SHOWS PROMISING PRELIMINARY SAFETY AND EFFICACY RESULTS IN THE PHASE I/II CLINICAL TRIAL (RUBY) OF PATIENTS WITH SEVERE SICKLE CELL DISEASE USING HIGHLY SPECIFIC AND EFFICIENT ASCAS12A ENZYME" @default.
• W4385658110 doi "https://doi.org/10.1097/01.hs9.0000967968.05170.e0" @default.
• W4385658110 hasPublicationYear "2023" @default.
• W4385658110 type Work @default.
• W4385658110 citedByCount "0" @default.
• W4385658110 crossrefType "journal-article" @default.
• W4385658110 hasAuthorship W4385658110A5002240997 @default.
• W4385658110 hasAuthorship W4385658110A5014878595 @default.
• W4385658110 hasAuthorship W4385658110A5015387863 @default.
• W4385658110 hasAuthorship W4385658110A5020447229 @default.
• W4385658110 hasAuthorship W4385658110A5021909393 @default.
• W4385658110 hasAuthorship W4385658110A5040299600 @default.
• W4385658110 hasAuthorship W4385658110A5041000924 @default.
• W4385658110 hasAuthorship W4385658110A5049744314 @default.
• W4385658110 hasAuthorship W4385658110A5068601602 @default.
• W4385658110 hasAuthorship W4385658110A5073201681 @default.
• W4385658110 hasAuthorship W4385658110A5076450548 @default.
• W4385658110 hasAuthorship W4385658110A5088514992 @default.
• W4385658110 hasBestOaLocation W43856581101 @default.
• W4385658110 hasConcept C10205521 @default.
• W4385658110 hasConcept C126322002 @default.
• W4385658110 hasConcept C143998085 @default.
• W4385658110 hasConcept C172680121 @default.
• W4385658110 hasConcept C197934379 @default.
• W4385658110 hasConcept C2776317666 @default.
• W4385658110 hasConcept C2778375690 @default.
• W4385658110 hasConcept C2779234561 @default.
• W4385658110 hasConcept C28328180 @default.
• W4385658110 hasConcept C54355233 @default.
• W4385658110 hasConcept C71924100 @default.
• W4385658110 hasConcept C86803240 @default.
• W4385658110 hasConceptScore W4385658110C10205521 @default.
• W4385658110 hasConceptScore W4385658110C126322002 @default.
• W4385658110 hasConceptScore W4385658110C143998085 @default.
• W4385658110 hasConceptScore W4385658110C172680121 @default.
• W4385658110 hasConceptScore W4385658110C197934379 @default.
• W4385658110 hasConceptScore W4385658110C2776317666 @default.
• W4385658110 hasConceptScore W4385658110C2778375690 @default.
• W4385658110 hasConceptScore W4385658110C2779234561 @default.
• W4385658110 hasConceptScore W4385658110C28328180 @default.
• W4385658110 hasConceptScore W4385658110C54355233 @default.
• W4385658110 hasConceptScore W4385658110C71924100 @default.
• W4385658110 hasConceptScore W4385658110C86803240 @default.
• W4385658110 hasIssue "S3" @default.
• W4385658110 hasLocation W43856581101 @default.
• W4385658110 hasLocation W43856581102 @default.
• W4385658110 hasOpenAccess W4385658110 @default.
• W4385658110 hasPrimaryLocation W43856581101 @default.
• W4385658110 hasRelatedWork W1556562895 @default.
• W4385658110 hasRelatedWork W2057339290 @default.
• W4385658110 hasRelatedWork W2087016115 @default.
• W4385658110 hasRelatedWork W2160729253 @default.
• W4385658110 hasRelatedWork W2335774562 @default.
• W4385658110 hasRelatedWork W2349164817 @default.
• W4385658110 hasRelatedWork W2363981502 @default.
• W4385658110 hasRelatedWork W3189762672 @default.
• W4385658110 hasRelatedWork W4251165208 @default.
• W4385658110 hasRelatedWork W4254901938 @default.
• W4385658110 hasVolume "7" @default.
• W4385658110 isParatext "false" @default.
• W4385658110 isRetracted "false" @default.
• W4385658110 workType "article" @default.